SB treatment decreased the lipid storage and inflammation within the liver and modulated the gut microbiota structure in an animal model of leptin-resistant obese and type 2 diabetic mice, suggesting that this dietary supplement yeast probiotic could impact the liver alteration by influencing the gut-liver axis [25]. This evidence concerns the gene LEP and type 2 diabetes mellitus.